|
|
|
| Curative Effects and Safety of Rosuvastatin Combined with Ezetimibe in Hyperlipidemia Elderly Patients with Acute Cerebral Infarction |
| Department of Neurology, Nanjing Pukou Certral Hospital, Nanjing 211800,China |
|
|
|
|
Abstract 【Objective】To study the effects and safety of the combination of ezetimibe and rosuvastatin on the levels of bloodlipids in elderly patients with acute cerebral infarction. 【Methods】A total of 89 patients with acute cerebral infarction were recruited and randomly assigned to group A (rosuvastatin 10mg/d，ezetimibe 10 mg/d，n=46) and group B(rosuvastatin 10 mg/d，n=43)．The observation targets of all patients were assessed after 2 weeks and 12 weeks of treatment. The changes of bloodlipids, alanine aminotransferase (ALT), aspartate aminotransferase (AST), and creatine kinase (CK) were compared before and after treatment．【Results】 Compared to before treatment, the levels of lowdensity lipoproteins (LDLC) after 2 weeks of treatment in both groups were decreased, dropping at ratios of 32.7% and 17.3%, respectively. However, after 12 weeks of treatment, the decreasing ratios were 48.4% and 27.2%. respectively; the levels of LDLC in group A dropped earlier and more quickly than in group B. There was a statistically significant difference (P<0.001). No correlation existed between improvement of liver enzyme level (ALT and AST) and muscle enzyme level (CK). The rate of reaching guideline target of LDLC 12 weeks after treatment was 56.5% (26 cases) in group A and 20.9% (9 cases) in group B; there was a statistically significant difference (P=0.002). The levels of total cholesterol (TC) fell by about 45% and 28% after 12 weeks of treatment, with significant difference between group A and group B (P=0.003). After 12 weeks of treatment the levels of triglycerides (TG) decreased, while levels of highdensity lipoproteins (HDLC) increased, but showed no statistical significance compared to before treatment. 【Conclusion】Our study demonstrated that it is feasible to initiate combination therapy in elderly patients with acute cerebral infarction，which can shorten the time it takes for LDLC levels to reach the guideline target and increase the rate of reaching the guideline target while not increasing liver or muscle toxicity.
|
|
Received: 11 April 2016
|
|
|
|
|
|
|
2016, Vol. 33 
